Abstract
Novartis is to acquire the US cancer diagnostics services company Genoptix in an all-cash deal that is worth US$470 M. Novartis will pay US$25 for all outstanding shares of Genoptix common stock, which represents a 27% premium over Genoptix’s closing price on the last day of trading before the deal was announced. The purchase will strengthen Novartis’ therapeutic oncology business and the acquired company will be integrated into Novartis’ Molecular Diagnostics unit.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
